135 related articles for article (PubMed ID: 37986346)
21. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
[TBL] [Abstract][Full Text] [Related]
22. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
23. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
25. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
29. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; Domingo-Domenech E; Climent F; Sanchez J; Perez Seoane C; Lopez Jimenez J; Garcia-Cosio M; Caballero D; Blanco Muñez OJ; Carpio C; Castellvi J; Martinez Pozo A; Gonzalez Farre B; Bendaña A; Aliste C; Gonzalez AJ; Gonzalez de Villambrosia S; Piris MA; Gomez Codina J; Mayordomo-Aranda E; Navarro B; Bellas C; Rodriguez G; Borrero JJ; Ruiz-Zorrilla A; Grande M; Montoto C; Cordoba R
Br J Haematol; 2021 Jan; 192(1):82-99. PubMed ID: 32426847
[TBL] [Abstract][Full Text] [Related]
31. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
32. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms.
Fang H; Khoury JD; Torres-Cabala CA; Ng SB; Xu J; El Hussein S; Hu S; Vega F; Li S; Tang Z; Tang G; Medeiros LJ; Wang W
Pathology; 2022 Dec; 54(7):893-899. PubMed ID: 35864006
[TBL] [Abstract][Full Text] [Related]
33. The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).
Julamanee J; Kayasut K; Lekhakula A
J Med Assoc Thai; 2015 Oct; 98(10):950-6. PubMed ID: 26638586
[TBL] [Abstract][Full Text] [Related]
34. [Expression of CDK6 and FOXM1 in peripheral T-cell lymphoma and their significance].
Feng HN; Shao XX; Bu P; Zhang F; Wang YJ; Xi YF; Guo WN
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):594-600. PubMed ID: 32486537
[No Abstract] [Full Text] [Related]
35. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
[TBL] [Abstract][Full Text] [Related]
36. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
[TBL] [Abstract][Full Text] [Related]
37. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
38. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
[TBL] [Abstract][Full Text] [Related]
40. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S; Yoshida S; Kato K; Choi I; Imamura Y; Kohno K; Henzan H; Tanimoto K; Ogawa R; Suehiro Y; Miyamoto T; Eto T; Ohshima K; Akashi K; Iwasaki H;
Int J Hematol; 2020 Jul; 112(1):74-83. PubMed ID: 32297159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
